Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

Reckamp, Karen L.; Lin, Huamao Mark; Cranmer, Holly; Wu, Yanyu; Zhang, Pingkuan; Kay, Stephen; Walton, Laura J; Shen, Jiayu; Popat, Sanjay; Camidge, D. Ross

doi:10.1080/03007995.2022.2100653

Cited by 2 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Indirect treatment comparison of phase III trials involving either alectinib or brigatinib for front-line treatment of ALK-rearranged NSCLCs showed comparable OS between these two treatments. 35 ALK-rearranged LUAD patients treated with alectinib usually exhibit a characteristic tumor volume dynamic with initial response with tumor volume decrease, nadir and subsequent regrowth; the percent tumor volume changes, evaluated by serial computed tomography, induced by alectinib at nadir (-90.9%) were more pronounced in patients who were treated as first-line, compared to those treated in second-line. 36…”

Section: Alectinibmentioning

confidence: 98%

See 1 more Smart Citation

Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Testa,

Castelli,

Pelosi

2023

Tumori

View full text Add to dashboard Cite

Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK-fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of ALK-rearranged LUADs when used as first- or second-line agents. However, resistance mechanisms greatly limit the durability of the therapeutic effects elicited by these TKIs. The molecular mechanisms responsible for these resistance mechanisms have been in part elucidated, but overcoming acquired resistance to ALK-derived therapy remains a great challenge. Some new therapeutic strategies under investigation aim to induce long-term remission in ALK-fusion positive LUADs.

show abstract

Section: Alectinibmentioning

confidence: 98%

“…Indirect treatment comparison of phase III trials involving either alectinib or brigatinib for front-line treatment of ALK -rearranged NSCLCs showed comparable OS between these two treatments. 35 …”

Section: Target Therapy Of Alk-rearranged Luadsmentioning

confidence: 99%

Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Testa,

Castelli,

Pelosi

2023

Tumori

View full text Add to dashboard Cite

show abstract

Bioinformatics-based prognostic analysis of non-small cell lung cancer

Zhao

Shu

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: With 75% of patients with non-small cell lung cancer (NSCLC) being found at an intermediate to advanced stage and a five-year survival rate of only 7%-17%, there is a need to find ways to improve the five-year survival rate of patients with NSCLC for prognosis. We used bioinformatics analysis of NSCLC samples from The Cancer Genome Atlas (TCGA) database to screen for differential genes and find multigene models for risk assessment of NSCLC patients, which is important for individualised clinical treatment and prognosis of NSCLC patients. Considering the limitations of the samples in this study, further validation in clinical and basic experiments is needed. Methods and results: The 519 samples associated with NSCLC were screened using bioinformatics in TCGA database, and the differential genes were selected by univariate analysis and Least Absolute Shrinkage and Selection Operator (LASSO) regression model. The most effective multi-gene model was selected by multi-gene analysis, and the validity of the multi-gene model was verified by survival analysis and Receiver Operating Characteristic (ROC) curves, and finally by the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and The mRNA differential genes were enriched KEGG and Gene Ontology (GO) databases. The GO enrichment analysis showed that the differential genes were associated with extracellular structural tissues, external encapsulated structural tissues and extracellular matrix tissues. enrichment indicated that the differential genes were associated with histidine metabolism, calcium signalling pathways and cytokine-cytokine receptor interactions, among others. In conclusion, a polygenic model consisting of 22 genes can be used as a tool for the prognosis of NSCLC. Conclusion: Polygenic models provide an ideal and effective approach to the prognosis of NSCLC. In this study, we screened a set of multigene models as a risk assessment model for the prognosis of NSCLC.

show abstract

Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase–positive non–small cell lung cancer using data from ALEX and final results from ALTA-1L

Cited by 2 publications

References 23 publications

Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting

Bioinformatics-based prognostic analysis of non-small cell lung cancer

Contact Info

Product

Resources

About